Caribou Biosciences, Inc. $CRBU Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its position in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 58.0% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,590,497 shares of the company’s stock after purchasing an additional 950,640 shares during the quarter. Renaissance Technologies LLC’s holdings in Caribou Biosciences were worth $4,922,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Creative Planning acquired a new stake in shares of Caribou Biosciences in the second quarter valued at approximately $25,000. Bronte Capital Management Pty Ltd. bought a new stake in shares of Caribou Biosciences during the fourth quarter valued at approximately $25,000. Hudson Bay Capital Management LP acquired a new position in shares of Caribou Biosciences during the second quarter worth approximately $30,000. Westmount Partners LLC acquired a new position in shares of Caribou Biosciences during the first quarter worth approximately $37,000. Finally, Russell Investments Group Ltd. grew its holdings in Caribou Biosciences by 80.0% in the 4th quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock worth $39,000 after buying an additional 10,824 shares in the last quarter. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Stock Up 1.9%

Shares of CRBU opened at $1.64 on Friday. The firm has a market capitalization of $162.66 million, a PE ratio of -1.15 and a beta of 2.38. The firm has a 50-day moving average price of $1.75 and a 200 day moving average price of $1.83. Caribou Biosciences, Inc. has a 52-week low of $1.38 and a 52-week high of $3.54.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $2.21 million. Caribou Biosciences had a negative net margin of 1,189.14% and a negative return on equity of 84.17%. On average, equities analysts expect that Caribou Biosciences, Inc. will post -1.15 EPS for the current year.

Analyst Upgrades and Downgrades

CRBU has been the topic of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Friday, July 17th. HC Wainwright boosted their price target on Caribou Biosciences from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.67.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.